Medical management of gastric cancer: A 2014 update

doi:10.3748/wjg.v20.i38.13637

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 38

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6675)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

544

WORD

197

HTML

3552

Tables (1-2)

170

Sum=4463

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1245

Download

967

Sum=2212

Oct 14, 2014 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (29)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 14, 2014; 20(38): 13637-13647
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13637

Medical management of gastric cancer: A 2014 update

Elena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Jeannelyn S Estrella, Mariela A Blum, Brian Badgwell, Prajnan Das, Shumei Song, Jaffer A Ajani

Elena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Mariela A Blum, Shumei Song, Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States

Jeannelyn S Estrella, Pathology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States

Brian Badgwell, Surgical Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States

Prajnan Das, Radiation Oncology, University of Texas, Anderson Cancer Center, Houston, TX 77030, United States

Author contributions: Elimova E and Ajani JA both contributed to writing the original paper; Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P and Song S contributed by editing the text and adding information pertaining to their field of expertise.

Correspondence to: Jaffer A Ajani, MD, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, 1515 Holcombe Blvd, (FC10.3022), Houston, TX 77030, United States. jajani@mdanderson.org

Telephone: +1-713-7922330 Fax: +1-713-7944535

Received: December 12, 2013
Revised: February 15, 2014
Accepted: May 19, 2014
Published online: October 14, 2014

Core Tip

Core tip: The standard of care for the management of localized gastric cancer continues to vary depending on where in the world this treatment takes place. In metastatic gastric cancer the outcomes remain poor. The first line treatment consists of trastuzumab in addition to chemotherapy in Her2 positive disease or fluoropyrimidine and platinum (with or without docetaxel or epirubicin) in Her2 negative disease. What is now clear is that second line chemotherapy, with either irinotecan, docetaxel or ramucirumab does improve overall survival.